<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599389</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2014/40</org_study_id>
    <nct_id>NCT02599389</nct_id>
  </id_info>
  <brief_title>Comparison of Angioplasty/Drug Coated Balloon/Laser + Drug Coated Balloon for Femoropopliteal Artery In-stent Restenosis</brief_title>
  <acronym>INTACT</acronym>
  <official_title>Economic Evaluation Comparing Standard Balloon Angioplasty Versus Drug-eluted Balloon or Laser-Excimer in Association With Drug-eluted Balloon in the Treatment of Femoropopliteal Artery In-stent Restenosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this multicenter triple-arm randomized study is to compare two innovative
      techniques with the gold standard currently used and providing unsatisfactory results for the
      In-Stent Restenosis (ISR) treatment in femoro-popliteal arteries. This protocol compares the
      use of drug-coated balloons (paclitaxel - antimitotic) used alone or in association with the
      Excimer Laser to recalibrate the vessel lumen into the stent by destroying the whole fibrous
      material to the standard angioplasty using plain balloons. INTACT study main objective is to
      assess cost-effectiveness ratio of the treatment of femoropopliteal artery in-stent
      restenosis by comparing these two innovative strategies and the standard one in terms of cost
      per Qaly (Quality adjusted life-years) gained at 18 months from a collective perspective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The publication show that there is probably an effectiveness gradient (expressed as a
      proportion of patients with in-stent restenosis a 18 months after the intervention of the
      first stenosis reduction): standard balloons would be less effective than active balloons
      themselves less effective than in combination with the excimer laser. Reducing the risk of
      In-Stent Restenosis has major implications for the treatment of patients because it reduces
      the use of arterial bypass or amputation, if unable to perform revascularization.

      Based on these promising results of efficiency, we can hypothesize that the active balloons
      in combination with the Excimer laser would improve the quality of life of patients while
      reducing the cost of their treatment, this compared to only assets balloons. This same
      improvement in quality of life with reduced costs of care would be observed for only assets
      compared to standard balloons. In health economic terms, it is therefore likely that the
      strategy combining assets balloons and Excimer laser is dominant over assets balloons
      themselves dominant over standard balloons.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental cost per Qaly gained at 18 months</measure>
    <time_frame>18 months after angioplasty</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental cost per avoided stenosis relapse at 18 months</measure>
    <time_frame>18 months after angioplasty</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>New In-stent restenosis during follow-up</measure>
    <time_frame>1 month, 6 months, 12 months and 18 months after angioplasty</time_frame>
    <description>No recurrence of in-stent restenosis &gt; 50% during follow-up with doppler . The three treatment groups are compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A major adverse event</measure>
    <time_frame>1 month, 6 months, 12 months and 18 months after angioplasty</time_frame>
    <description>Absence of major event during follow-up as death, lower limb amputation or lack of required revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the walking procedure</measure>
    <time_frame>Before and 12 months after angioplasty</time_frame>
    <description>Improvement in the walking procedure performing by Strandness test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>6 months, 12 months and 18 months after angioplasty</time_frame>
    <description>Clinical improvement by the Rutherford classification at 6, 12 and 18 months. This improvement is objectified by a decrease in category 1 or several classes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure Index</measure>
    <time_frame>6 months, 12 months and 18 months after angioplasty</time_frame>
    <description>Index :ratio of brachial pressure and compressible leg artery pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>new treatment for the treated lesion</measure>
    <time_frame>6 months, 12 months and 18 months after angioplasty</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>revascularization, with restenosis of the treated lesion</measure>
    <time_frame>6 months, 12 months and 18 months after angioplasty</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence of clinical symptoms</measure>
    <time_frame>6 months, 12 months and 18 months after angioplasty</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood ultrasonic doppler velocimetry</measure>
    <time_frame>6 months, 12 months and 18 months after angioplasty</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Angioplasty, Balloon</condition>
  <arm_group>
    <arm_group_label>Standard balloon</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Angioplasty with use of standard balloons</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug-coated balloons</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Angioplasty with use of drug-coated balloons</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug-coated balloons and laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Angioplasty with use of drug-coated balloons in association with Excimer Laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-coated balloons</intervention_name>
    <arm_group_label>Drug-coated balloons</arm_group_label>
    <arm_group_label>Drug-coated balloons and laser</arm_group_label>
    <other_name>In.Pact (Medtronic)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Excimer Laser</intervention_name>
    <arm_group_label>Drug-coated balloons and laser</arm_group_label>
    <other_name>SPECTRANETICS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient of age &gt; 18 years

          -  Patient with previously peripheral implanted stent(s) located in or extending to the
             popliteal artery

          -  Patient who received this stent between 3-36 months before inclusion

          -  Patient with one or more in-stent restenosis lesion(s) &gt; 70% in the same arterial
             segment in association with clinical symptoms of claudication or an critical limb
             ischemia with Rutherford classification of 2, 3, 4 or 5

          -  Reference vessel diameter between 4 and 7 mm

          -  Patient affiliated to a social security regimen

          -  EC-approved consent form signed by the participant and the investigator (must be
             signed prior initiation of any study related intervention)

        Exclusion Criteria:

          -  Life expectancy &gt;18 months

          -  Patient already included in this study (recruitment of the contralateral leg is not
             allowed)

          -  Patient contraindicated for the use of antiplatelet therapy

          -  Pregnant or breast-feeding women

          -  Patient with a target limb infection being treated

          -  Patient with a procoagulant blood disease

          -  Patient with history of contrast agents allergies

          -  Patient with intolerance to paclitaxel

          -  Patient with severe renal impairment (GFR &lt;30 ml / min / 1.73 m²) or patient with a
             creatinine clearance &lt;15 ml / min

          -  External compression of previously implanted stent

          -  Patient participating in any clinical trial using another investigational drug or
             product which could interfere with the interpretation of the trial results.

          -  Patient under trusteeship or guardianship

        Angiographic exclusion criteria :

          -  Inflow (above) severe lesion &gt;70% or occlusion untreated satisfactorily (residual
             lesion&gt; 50%) before the management of the target lesion

          -  Perforation, dissection or lesions on the arterial network access requiring an
             assumption prior to randomization

          -  Stent fracture grade 4 or 5 at the target lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric DUCASSE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine BENARD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Unité de Soutien Méthodologique à la Recherche clinique et épidémiologique; University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric DUCASSE, MD, PhD</last_name>
    <phone>+335 56 79 55 25</phone>
    <email>eric.ducasse@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier PERIOT</last_name>
    <phone>+335 57 82 04 59</phone>
    <email>olivier.periot@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Rhône Durance</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme BRUNET, MD</last_name>
      <phone>+334 90 14 81 90</phone>
      <email>jeromebrunet2@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon RINCKENBACH, MD, PhD</last_name>
      <phone>+333 81 66 80 52</phone>
      <email>simon.rinckenbach@univ-fcomte.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux - Hospital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric DUCASSE, MD, PhD</last_name>
      <phone>+335 56 79 55 25</phone>
      <email>eric.ducasse@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Olivier PERIOT</last_name>
      <phone>+335 57 82 04 59</phone>
      <email>olivier.periot@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenio ROSSET, MD, PhD</last_name>
      <phone>+334 73 75 15 10</phone>
      <email>erosset@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric STEINMETZ, MD, PhD</last_name>
      <phone>+333 80 29 33 85</phone>
      <email>eric.steinmetz@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LERMUSIAUX, MD, PhD</last_name>
      <phone>+334 72 11 68 34</phone>
      <email>patrick.lermusiaux@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Timone Adultes</name>
      <address>
        <city>Marseille</city>
        <zip>130005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann GOUEFFIC, MD, PhD</last_name>
      <phone>+332 40 16 50 93</phone>
      <email>yann.goueffic@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Les Fleurs</name>
      <address>
        <city>Ollioules</city>
        <zip>83190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe COMMEAU, MD, PhD</last_name>
      <phone>+334 94 06 98 82</phone>
      <email>p.commeau@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou - AP-HP de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc SAPOVAL, MD, PhD</last_name>
      <phone>+331 56 09 37 40</phone>
      <email>marc.sapoval2@egp.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinique de L'Europe</name>
      <address>
        <city>Rouen</city>
        <zip>76100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean SABATIER, MD</last_name>
      <phone>+332 32 18 12 76</phone>
      <email>j.sabatier@clinique-europe.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de St Etienne</name>
      <address>
        <city>St Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre FAVRE, MD, PhD</last_name>
      <phone>+334 77 82 83 35</phone>
      <email>j.pierre.favre@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nabil CHAKFE, MD, PhD</last_name>
      <phone>+333 69 55 08 88</phone>
      <email>nabil.chakfe@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine SAUGUET, MD</last_name>
      <phone>+335 62 21 16 99</phone>
      <email>asauguet@clinique-pasteur.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>November 25, 2016</last_update_submitted>
  <last_update_submitted_qc>November 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in-stent restenosis; drug-coated balloons; Excimer Laser, cost effectiveness study, quality of life</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

